Loris Riccardo Lopetuso

List of Publications by Year
in descending order

96 papers	5,890 citations	109137 35 h-index	79541 73 g-index
98 all docs	98 docs citations	98 times ranked	9735 citing authors

#	Article	IF	Citations
1	Proteobacteria: A Common Factor in Human Diseases. BioMed Research International, 2017, 2017, 1-7.	0.9	673
2	Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathogens, 2013, 5, 23.	1.6	631
3	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Digestive and Liver Disease, 2018, 50, 421-428.	0.4	377
4	Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. Nutrients, 2019, 11, 2393.	1.7	374
5	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	6.1	290
6	The Gut Barrier. Journal of Clinical Gastroenterology, 2012, 46, S12-S17.	1.1	171
7	Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, 2013, 1-9.	0.9	156
8	European Crohnâ€™s and Colitis Organisation Topical Review on Treatment Withdrawal [â€˜Exit Strategiesâ€™] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 17-31.	0.6	151
9	Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Frontiers in Immunology, 2013, 4, 181.	2.2	149
10	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. Digestive Diseases, 2018, 36, 56-65.	0.8	146
11	Role and mechanisms of action ofEscherichia coliNissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology, 2016, 22, 5505.	1.4	141
12	Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals. Digestive and Liver Disease, 2018, 50, 635-639.	0.4	137
13	Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. Gastroenterology Research and Practice, 2017, 2017, 1-11.	0.7	119
14	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infectionâ€”single versus multiple infusions. Alimentary Pharmacology and Therapeutics, 2018, 48, 152-159.	1.9	117
15	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9362-E9370.	3.3	110
16	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases, 2016, 34, 269-278.	0.8	105
17	Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. European Review for Medical and Pharmacological Sciences, 2019, 23, 8075-8083.	0.5	99
18	Gut Microbiota Profiling and Gutâ€“Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Frontiers in Microbiology, 2018, 9, 675.	1.5	88

#	Article	IF	Citations
19	Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis and Tissue Repair, 2012, 5, 18.	3.4	78
20	Can We Predict the Efficacy of Anti-TNF-Î± Agents?. International Journal of Molecular Sciences, 2017, 18, 1973.	1.8	73
21	The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. European Review for Medical and Pharmacological Sciences, 2015, 19, 1068-76.	0.5	73
22	Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. International Journal of Molecular Sciences, 2019, 20, 183.	1.8	70
23	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcoholâ€associated liver disease. Liver International, 2020, 40, 878-888.	1.9	68
24	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology, 2015, 21, 12322.	1.4	65
25	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-Î± on the Liver. International Journal of Molecular Sciences, 2018, 19, 2199.	1.8	62
26	Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2018, 10, 1074.	1.7	62
27	Esophageal microbiome signature in patients with Barrettâ€™s esophagus and esophageal adenocarcinoma. PLoS ONE, 2020, 15, e0231789.	1.1	58
28	Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. Minerva Gastroenterologica E Dietologica, 2018, 64, 351-362.	2.2	55
29	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. International Journal of Molecular Sciences, 2017, 18, 2020.	1.8	53
30	Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. Current Pharmaceutical Design, 2014, 20, 4565-4569.	0.9	51
31	Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. Nutrients, 2019, 11, 2281.	1.7	47
32	Role of Microbiota and Innate Immunity in RecurrentClostridium difficileInfection. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	43
33	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.4	40
34	Impact of COVIDâ€19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a highâ€volume Italian inflammatory bowel disease centre. United European Gastroenterology Journal, 2020, 8, 775-781.	1.6	40
35	The gastrointestinal microbiome â€“ Functional interference between stomach and intestine. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 995-1002.	1.0	39
36	Gut Virome and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1708-1712.	0.9	39

#	Article	IF	Citations
37	Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities. European Review for Medical and Pharmacological Sciences, 2019, 23, 795-810.	0.5	39
38	Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. Digestive and Liver Disease, 2013, 45, 1017-1021.	0.4	38
39	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	1.7	36
40	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Diseases, 2020, 26, 1306-1314.	0.9	35
41	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. Microorganisms, 2020, 8, 1140.	1.6	35
42	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110066.	1.4	34
43	Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System. Journal of Visualized Experiments, 2013, , e50843.	0.2	33
44	Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for â€˜gut barrier protectorsâ€™ in IBD?. United European Gastroenterology Journal, 2014, 2, 113-122.	1.6	31
45	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcoholâ€Preferring Rats. Alcoholism: Clinical and Experimental Research, 2018, 42, 2313-2325.	1.4	29
46	Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opinion on Biological Therapy, 2020, 20, 343-351.	1.4	29
47	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. Transplantation Proceedings, 2016, 48, 402-407.	0.3	26
48	The Use of Probiotics in Different Phases of Diverticular Disease. Reviews on Recent Clinical Trials, 2018, 13, 89-96.	0.4	25
49	Bacillus clausii and gut homeostasis: state of the art and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	1.4	23
50	Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel. Inflammatory Bowel Diseases, 2018, 24, 2198-2210.	0.9	23
51	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. Digestive and Liver Disease, 2020, 52, 1002-1010.	0.4	23
52	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS ONE, 2017, 12, e0186575.	1.1	23
53	Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin. Mini-Reviews in Medicinal Chemistry, 2015, 16, 179-185.	1.1	22
54	Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis. Inflammatory Bowel Diseases, 2017, 23, 392-403.	0.9	19

#	Article	IF	Citations
55	Interleukin 1Î² Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factorâ€“Independent Ulcerative Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 151-171.	2.3	19
56	Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease. Digestive Diseases, 2016, 34, 202-209.	0.8	18
57	Rifaximin for the treatment of irritable bowel syndrome â€“ a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 983-991.	1.0	18
58	Beyond the HLA Genes in Gluten-Related Disorders. Frontiers in Nutrition, 2020, 7, 575844.	1.6	18
59	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. Digestive and Liver Disease, 2016, 48, 391-398.	0.4	17
60	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohnâ€™s disease. Expert Opinion on Investigational Drugs, 2018, 27, 543-551.	1.9	17
61	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. Digestive and Liver Disease, 2020, 52, 1390-1395.	0.4	16
62	Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis. Nutrients, 2022, 14, 2664.	1.7	16
63	Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Beneficial Microbes, 2020, 11, 519-525.	1.0	13
64	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	0.8	13
65	Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea. European Review for Medical and Pharmacological Sciences, 2017, 21, 873-883.	0.5	13
66	Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Review of Gastroenterology and Hepatology, 2018, 12, 899-906.	1.4	12
67	Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?. World Journal of Gastroenterology, 2016, 22, 10198.	1.4	12
68	Anti-tumor necrosis factor Î± therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. World Journal of Gastroenterology, 2019, 25, 1465-1477.	1.4	11
69	A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohnâ€™s disease-like ileitis. PLoS ONE, 2017, 12, e0174121.	1.1	10
70	Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohnâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 2921.	1.8	8
71	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The â€œEPIMICI â€“ San Marinoâ€• study. Digestive and Liver Disease, 2019, 51, 218-225.	0.4	8
72	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohnâ€™s disease patients. Expert Review of Gastroenterology and Hepatology, 2020, 14, 857-865.	1.4	7

#	Article	IF	Citations
73	Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment. European Journal of Gastroenterology and Hepatology, 2020, 32, 1527-1532.	0.8	6
74	High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. European Review for Medical and Pharmacological Sciences, 2016, 20, 297-300.	0.5	6
75	Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia. Inflammatory Bowel Diseases, 2021, 27, 902-913.	0.9	5
76	Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients. Gastroenterology, 2021, 161, 368-369.	0.6	5
77	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World Journal of Gastroenterology, 2016, 22, 9727.	1.4	5
78	Anti-TNF-Î±-induced psoriasiform lesions in IBD: an abnormal immune activation or a â€˜patchy cutaneousâ€™ immune suppression?. Gut, 2014, 63, 699-701.	6.1	4
79	Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 764-765.	0.9	4
80	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. Endoscopy International Open, 2020, 08, E980-E984.	0.9	4
81	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096874.	1.4	4
82	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. Computers in Biology and Medicine, 2019, 104, 335-338.	3.9	3
83	Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study. Journal of Personalized Medicine, 2022, 12, 1005.	1.1	3
84	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
85	Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries. European Review for Medical and Pharmacological Sciences, 2016, 20, 3891-3901.	0.5	2
86	Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: a multidisciplinary management experience. European Review for Medical and Pharmacological Sciences, 2020, 24, 564-570.	0.5	2
87	Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy. Gastroenterology Nursing, 2021, 44, E59-E66.	0.2	1
88	Development and Validation of Predictive Assessment of Complicated Diverticulitis Score. Journal of Personalized Medicine, 2021, 11, 80.	1.1	1
89	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World Journal of Gastroenterology, 2021, 27, 8047-8057.	1.4	1
90	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opinion on Biological Therapy, 2022, 22, 313-320.	1.4	1

#	Article	IF	Citations
91	Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. European Review for Medical and Pharmacological Sciences, 2021, 25, 5826-5835.	0.5	1
92	OP29 ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer. Journal of Crohn's and Colitis, 2019, 13, S021-S022.	0.6	0
93	P497 IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S360-S361.	0.6	0
94	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. Clinical Gastroenterology and Hepatology, 2021, 19, 205-206.	2.4	0
95	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines, 2021, 9, 248.	2.1	0
96	A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors. European Review for Medical and Pharmacological Sciences, 2020, 24, 8469-8476.	0.5	0